This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

XtalPi Holdings Limited
晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board (the "**Board**") of directors (the "**Directors**") of XtalPi Holdings Limited (the "**Company**") hereby announces the unaudited condensed consolidated results of the Company and its subsidiaries (collectively, the "**Group**", "**we**" or "**our**") for the six months ended 30 June 2026 (the "**Reporting Period**"), together with the comparative figures for the corresponding period of 2025. These unaudited condensed consolidated results of the Group have been reviewed by the audit committee of the Company (the "**Audit Committee**").

FINANCIAL SUMMARY

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**393,627**	517,076
Research and development expenses	**(367,838)**	(221,527)
(Loss)/profit for the period	**(224,944)**	75,609
Adjusted net (loss)/profit (non-IFRS measure)*	**(105,511)**	141,628

* Adjusted net (loss)/profit is not defined under the IFRS Accounting Standards (the "**IFRS**"). It represents the (loss)/profit for the period adjusted by adding back (i) share-based compensation expenses, and (ii) interest expenses on convertible bonds.

1. BUSINESS OVERVIEW

Artificial intelligence (AI) first demonstrated its productivity-enhancing value in digital applications such as content generation and software development. Now, its application boundaries are rapidly extending from the digital world into scientific R&D and the physical world. AI for Science (AI4S), or AI-enabled scientific innovation, connects scientific discovery with technological innovation. Leaders of the global technology industry and eminent academics at leading research institutions alike regard AI4S as one of the most transformative frontiers in the next stage of AI development, with the potential to reshape the scientific research paradigm, expand the frontiers of human knowledge, and usher in a new wave of technological revolution and industrial transformation. Industry research indicates that the AI4S market is on track to exceed USD140 billion, with current penetration still very low. Over the longer term, the AI4S end market has the potential to reach the trillion-USD level, as capabilities extend into downstream value chains and a broader range of scientific research scenarios. The Group believes that the essence of AI4S lies in building intelligent infrastructure that bridge the digital and physical worlds, forming end-to-end capabilities spanning scientific reasoning through experimental validation, and advancing AI from isolated tools that assist scientific research toward autonomous scientific discovery. Under this model, AI moves beyond executing individual tasks in response to instructions and is able, in actual scientific research activities, to autonomously undertake a broader range of research functions, including task orchestration, specialized decision-making, experimental validation and iterative optimization.

On this basis, the Group has taken the lead in defining five levels of autonomous scientific discovery: L1 Tools (static tools), L2 Co-Pilots (assisting humans), L3 Agents (independently completing parts of a workflow), L4 Domain-Specific Autonomous (full-workflow autonomy within a specific domain) and L5 General Autonomous AI4S (autonomous AI-enabled scientific innovation across a broad range of domains). This framework reflects the Group's fundamental view of autonomous scientific discovery: its essence lies not in the simple aggregation of models, robots or computing resources, but in AI's ability to autonomously undertake real-world scientific research tasks, independently make specialized decisions and continuously advance scientific discovery.

AI4S: Connecting Digital & Physical Worlds to Enable Autonomous Scientific Discovery

Drawing on extensive experience and capabilities accumulated through real-world projects, the Group has currently achieved end-to-end L4 autonomous discovery capabilities across multiple R&D scenarios. Through the unified orchestration of scientific models and automated experimental facilities by agents, the Group has developed a closed-loop R&D process covering task planning, experimental validation and feedback-driven iteration. In representative scenarios such as high-throughput experimentation and compound library synthesis, the Agentic HTE (Autonomous High-Throughput Experimentation) platform can independently match experimental conditions, generate experimental plans, schedule automated experiments, analyse results and plan subsequent experiments based on reaction objectives defined in natural language, enabling closed-loop optimization of reaction conditions. The Agentic Synthesis (Autonomous Molecular Synthesis) platform connects the entire process from raw material verification and project creation to experimental condition generation and automated execution, enabling the end-to-end autonomous advancement of compound library synthesis tasks based on target molecule requirements.

Extending autonomous scientific discovery from specific domains and individual workflows to more complex scientific research tasks and broader application scenarios continues to face three key constraints. First, the supply of high-quality scientific data remains insufficient, while reusable evaluation standards and engineering foundations require further development. Second, research plans generated by AI have yet to be fully connected with real-world experimental execution. Third, AI's capabilities in continuous learning, recursive improvement, cross-domain transfer and original discovery need to be further enhanced. To address these constraints and build the end-to-end capabilities required for autonomous scientific discovery, the Group continues to embed AI across its R&D operations and advance the development of an AI-native organization, progressively integrating Scientific Agents into R&D, project management and organizational collaboration workflows. Drawing on more than a decade of AI4S R&D and industry experience, the Group has built integrated scientific research infrastructure connecting the digital and physical worlds, which continues to be validated, iterated and enhanced through real-world projects.

1.1 Technology Engine: An AI-Driven Approach to R&D Bridging the Digital and Physical Worlds

To support the end-to-end execution of complex scientific research tasks, the Group has progressively developed a four-layer core technology architecture comprising Genius Agent, the intelligent hub; Scientific AI; Physical AI; and the Data Moat, its high-quality data foundation, through its extensive experience in internal R&D programs and external service projects. Rather than a simple combination of individual technologies, this architecture represents industrial-grade integrated scientific research infrastructure developed through continuous deployment, validation and iteration in real-world industrial R&D workflows.

- ***Genius Agent (Intelligent Hub): Orchestrating Complex Research Tasks***

  Serving as the core orchestration hub and R&D capability matrix, Genius Agent supports a multi-agent system that combines global planning with scenario-specific execution and incorporates specialized skills and tools. Across exploratory scenarios requiring continuous hypothesis testing, multi-objective optimization and experimental iteration, as well as process-driven scenarios with clearly defined responsibilities and relatively standardized workflows, Genius Agent breaks down complex research objectives, centrally orchestrates scientific models, specialized tools, R&D workflows and data resources, coordinates task execution among specialized agents, and uses project context to sustain long-cycle R&D programs.

- ***Scientific AI: Providing Specialized Scientific Computing and Predictive Capabilities***

  Across drug discovery, chemistry and materials R&D, the Group continues to build a comprehensive suite of AI capabilities covering diverse molecular modalities and specialized tasks, including small molecules, large molecules, peptides and oligonucleotide therapeutics. It has also launched a series of industry-leading proprietary models and specialized platforms. SureRoute, the Group's self-evolving AI retrosynthesis system, provides one example. In an evaluation involving 350 real-world industrial molecules, it reduced the chemical hallucination rate, a key performance metric for retrosynthesis AI, to 4.6%. This was approximately one-sixth of the rate recorded by leading large models in the industry. Its top-1 route recommendation accuracy reached 74.3%.

- ***Physical AI: Intelligent Robotic Labs Enabling Physical Execution and Validation***

  The Group's internally developed, world-leading intelligent robotic laboratories constitute the core platform through which Physical AI is embedded into R&D workflows. They translate experimental plans generated by scientific models and agents into standardized, automated and traceable workflows for robotic execution. Experimental results and process data are systematically captured and fed back into the scientific models and agents to support subsequent prediction, decision-making and experimental iteration. Over the past several years, the Group has continuously iterated its autonomous experimentation platform and deployed more than 300 automated workstations worldwide across over 20 categories of R&D applications. These capabilities support the Group's internal drug and advanced materials R&D, while also enabling it to provide automated platform deployment and related technical services to external customers. The Group has collaborated with several major pharmaceutical companies in the United States and South Korea on drug R&D and chemical reaction condition optimisation, and has further extended these capabilities into fields including new energy.

- ***Data Moat (High-Quality Data Foundation): Supporting Model Validation and Continuous Optimization***

  The Group continues to build a high-quality data foundation integrating publicly available scientific data, proprietary R&D data and real-world experimental data generated by Physical AI. By structuring and governing scientific literature, patents, experimental records and other sources, the Group has developed traceable data assets encompassing experimental results, process parameters and failed experiments. It has established proprietary datasets across different drug modalities, with certain key data types offering a scale advantage of several to tens of times compared with publicly available datasets. The continuous operation of Physical AI further enables this data foundation to expand dynamically through real-world projects. The system has supported more than 100 drug and advanced materials discovery projects, consistently generating over 50,000 reaction yield data points and 300,000 process data points each month. It has accumulated more than 500,000 real-world experimental records, approximately 80% of which are negative results from failed experiments that are relatively scarce in published literature. These data are continuously used for domain-specific model training, performance validation and R&D plan optimization, helping to identify unproductive pathways, calibrate prediction boundaries and improve reliability in complex R&D tasks.

Technology Engine: A Four-Layer Core Architecture



1.2 Business Model: Deep Synergies Across the Business Portfolio

Leveraging its R&D system integrating the digital and physical worlds, the Group has developed a dual-engine business structure centered on Drug Discovery Solutions and AI4S Intelligent Solutions, combining recurring cash flow with the potential for asset value realization.

- **Drug Discovery Solutions are built around the Group's AI-driven drug discovery capabilities,** encompassing platform-based collaboration services and the out-licensing of internally developed assets. Through platform-based collaboration services, the Group leverages its AI drug discovery capabilities to provide R&D services to customers, generating stable cash flow. Its proprietary pipeline assets may generate upfront licensing payments, milestone payments and potential sales royalties through out-licensing, co-development and other arrangements, progressively realising asset value and expanding the Group's long-term growth potential.

- **AI4S Intelligent Solutions** provide customers with AI4S infrastructure comprising AI4S Intelligent Robotic Labs (Physical AI) and AI4S Intelligent Services. AI4S Intelligent Robotic Labs (Physical AI) provides intelligent experimental infrastructure for scientific research applications, supporting standardised, high-throughput experimental execution and the systematic generation of high-quality, traceable experimental data. They underpin the rapid operation of an integrated dry- and wet-lab R&D closed loop capable of autonomous iteration. AI4S Intelligent Services leverages innovative molecular building blocks, the VAST Virtual Compound Library and a high-throughput autonomous synthesis platform to help customers to explore broader chemical space and rapidly validate molecular designs through compound synthesis.

The two businesses operate in deep synergy and together form a recursively improving closed loop. As a core application scenario, Drug Discovery Solutions continuously generates high-quality data, requirements for experimental validation and momentum for technological iteration. These in turn drive capability upgrades and expansion into new applications for AI4S Intelligent Solutions. The general-purpose technology foundation and standardized experimental capabilities developed through AI4S Intelligent Solutions provide Drug Discovery Solutions with more efficient and reusable R&D infrastructure, supporting the creation of high-value drug assets. **Through continuous interaction in real-world R&D settings, the two businesses form a self-evolving closed loop comprising application-driven development, experimental validation, data feedback and continuous capability enhancement.** This drives ongoing self-optimization across scientific prediction, experimental execution and intelligent orchestration, further strengthening the Group's platform-based competitive advantages.

At the same time, the platform's foundational capabilities have been successfully extended to sectors beyond pharmaceuticals, including advanced materials and consumer health, further demonstrating the commercial potential of deploying the same technology foundation across industries and creating broader growth opportunities for the Group.

Two Businesses, One Self-Improving Closed Loop



1.3 Recent Business Highlights: Continued Validation of the Technology Foundation and Faster Delivery of Business Milestones

As the technology platform continues to be deployed and commercially validated in drug discovery and AI4S, the Group has become significantly more efficient at discovering and advancing drug pipelines, with a number of important business breakthroughs.

Leading AI4S infrastructure: The industry's only full-stack AI4S infrastructure system connecting robotic laboratories, Scientific Agents and autonomous synthesis, and the first to achieve scaled commercial deployment. During the Reporting Period, revenue from AI4S Intelligent Solutions **increased by 136.4% year on year.**

AI drug R&D platform with the broadest modality coverage: The Group has built four core technology platforms covering small molecules, large molecules, peptides and oligonucleotides. In each segment, it has accumulated high-quality, standardized proprietary data and trained industry-leading generative and predictive models on that data.

Efficiently building a differentiated and extensive pipeline: The Group has established a highly differentiated portfolio of partnered and proprietary pipelines. Three pipelines have entered clinical trials, more than 10 are IND-approved or IND-enabling, and nearly 10 have reached the PCC stage. By 2027, **more than 10 pipelines are expected to be in the clinical stage, more than 10 at the IND-approved or IND-enabling stage, and approximately 20 at the PCC stage;**

"Real-world" AI breaking through conventional drug R&D bottlenecks: the Group continues to validate its ability to solve complex R&D problems across multiple drug modalities, including **antibody programs that have achieved mechanism innovation, therapeutic-window optimization and breakthroughs in safety and developability;** certain molecular glue pipelines achieving picomolar target protein degradation activity within one quarter; an oral cyclic peptide program identifying hit compounds within two months of target confirmation; and an IgA nephropathy oligonucleotide program obtaining strong non-human primate efficacy data approximately seven months after initiation;

Strong recognition from leading customers and all-round collaboration: The Group continues to deepen all-round collaboration with leading global customers, covering **platform services, model licensing, pipeline transactions and AI4S infrastructure deployment.** Overseas deliveries and repeat orders from leading customers fully validate the sophistication of the Group's business model.

Launch of a self-evolving AI retrosynthesis chemistry system: The "chemical hallucination" rate was reduced to 4.6%, only one-sixth that of leading large models in the industry; top-1 recommended route accuracy reached 74.3%, 2.2 to 3.5 times that of existing specialized and general-purpose models, significantly improving the reliability of AI-assisted synthetic route design and R&D translation efficiency.

The world's first comprehensive open scientific research platform to realize a Physical AI closed loop: The Group officially launched **the XtalPi Science Scientific AI platform and the Genius Agent suite of Scientific Agents,** advancing the standardization and platform-based upgrade of internal scientific research capabilities and building underlying AI4S infrastructure that industry partners and research institutions worldwide can access on demand.

Deploying leading biological simulation technologies: Through investment, incubation and other approaches, the Group has deployed biological models and validation capabilities, including virtual cells, human organ-on-a-chip systems and organoids, extending R&D capabilities from molecular design to mechanistic research, translational prediction and efficacy validation at the cellular and tissue levels, and further improving the translational success rate of preclinical R&D.

1.4 Outlook: A Comprehensive Industry Footprint Positioned to Capture AI-Driven Industry Growth

The AI4S industry, particularly the AIDD field, is in a stage of rapid expansion. With end-to-end capabilities spanning R&D infrastructure through proprietary assets, the Group is well positioned to benefit from the following business drivers:

- **Short term:** The rapid expansion of AI-driven drug discovery is driving significant growth in demand for novel molecule synthesis and R&D data. Leveraging its AI-native experimentation system and leading intelligent laboratories, the Group is poised to capture incremental orders from leading pharmaceutical companies, supporting sustainable, rapid business growth.

- **Medium term:** Pharmaceutical companies in China and overseas continue to show strong demand to replenish their pipelines with innovative assets, with a corresponding increase in demand for advanced R&D services and high-quality assets. The Group generates stable revenue from platform-based technology services while realizing value from high-quality internally developed pipeline assets through pipeline transactions, creating dual growth drivers of platform services and asset monetization.

- **Medium to long term:** Leveraging the efficiency of its AI-driven R&D capabilities, the Group continues to incubate high-quality proprietary pipelines. As these pipelines advance into regulatory filings and into clinical development, the Group is on course to establish a dual-engine growth model combining R&D services with proprietary drug development, moving beyond the growth limitations of traditional business models and supporting a substantial uplift in financial performance.

- **Long term:** AI4S is driving a shift in pharmaceutical R&D from empirical trial and error toward a data- and intelligence-driven approach. The Group's end-to-end intelligent R&D system can significantly improve R&D efficiency, reduce costs and increase success rate, while continuously accumulating proprietary data and algorithmic advantages. This will enable the Group to build highly differentiated core capabilities and capture the long-term development benefits arising from the industry's transformation.

2. FINANCIAL PERFORMANCE

For the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the corresponding period of last year, which reflected the recognition of an upfront payment of USD51.0 million from a major pipeline licensing project in the corresponding period last year. The collaboration progressed well during the Reporting Period, with the Group receiving a second payment of USD19.0 million. Excluding the impact of such pipeline licensing project, revenue increased by 73.8% year on year. In particular, revenue from AI4S Intelligent Solutions increased by 136.4% year on year, while both Intelligent Robotic Labs and Intelligent Services maintained rapid growth.

In the first half of 2026, the Group recorded a net loss of RMB224.9 million and an adjusted net loss of RMB105.5 million, primarily attributable to the year-on-year decrease in revenue and a 66.0% year-on-year increase in R&D expenses. The increase in R&D expenses was mainly driven by the Group's continued increase in investment in autonomous laboratories, agentic systems, pipeline programs under development and multimodal technology platforms.

As of 30 June, 2026, the Group's total cash balance[1] amounted to RMB8,671.2 million. Its strong cash position provides robust support for continued R&D investment, further strengthening XtalPi's leading position in AI4S.

3. BUSINESS DEVELOPMENT

3.1 Drug Discovery Solutions: Platform Technologies Accelerating Pipeline Assets and Commercialization

During the Reporting Period, revenue from the Drug Discovery Solutions business amounted to approximately RMB200.1 million, compared with RMB435.2 million in the corresponding period of last year. The change was primarily attributable to the high base in the corresponding period of last year, when an upfront payment of USD51.0 million from a major pipeline licensing project was recognized in the corresponding period last year. The collaboration progressed well during the Reporting Period, with the Group receiving a second payment of USD19.0 million. Meanwhile, the Group is actively advancing its strategic progression from services to assets. By building technology platforms across multiple drug modalities and deploying proprietary innovative drug pipelines with high clinical value and commercialization potential, the Group is laying the foundation for long-term value realization. The short-term revenue fluctuation reflects only a temporary base effect and does not alter the continued execution of the Group's core businesses or affect the advancement of its medium- to long-term development strategy.

[1] Cash balance comprises cash and cash equivalents, bank deposits, the current portion of financial assets at fair value through profit or loss, and restricted cash as of 30 June, 2026.

3.1.1 Drug R&D Platform and Pipeline Progress: Breakthroughs Across Multiple Therapeutic Modalities, Accelerating Clinical Translation

The Group continues to build AI-native platform capabilities for multimodal drug R&D and has established a systematic technology portfolio covering key drug modalities, including small molecules, large molecules, oligonucleotides and peptides. Centered on high-quality data assets, advanced AI models and intelligent robotic laboratories, each platform connects key stages spanning target understanding, molecular design, function prediction, candidate optimization and experimental validation. This is driving a shift in the R&D model from experience-driven, sequential trial and error toward data- and model-driven development with integrated dry- and wet-lab closed-loop iteration. By accumulating foundational algorithms, experimental capabilities and project experience across different drug modalities, the Group continues to improve the efficiency of candidate discovery, its developability optimization capabilities and the certainty of pipeline translation, laying a solid foundation for a diversified portfolio of innovative drug assets and the expansion of external collaborations.

In real-world projects, AI has been deeply integrated into multiple highly complex R&D scenarios, including the discovery of molecular glue candidates with high degradation activity, the remediation of protein aggregation issues and immunogenicity optimization for large molecules, as well as sequence generation and personalized modification recommendations for oligonucleotide therapeutics. These applications continue to create incremental value that is difficult to achieve using conventional methods, demonstrating the Group's "real-world" AI application capabilities across the full drug development workflow.

Among the Group's proprietary and partnered pipelines, three have entered the clinical stage, more than 10 pipelines are IND-approved or IND-enabling, and nearly 10 pipelines have reached the PCC stage, spanning multiple therapeutic modalities, including small molecules, molecular glues, antibodies, cell therapies, peptides and oligonucleotides. By 2027, more than 10 pipelines are expected to be in the clinical stage, more than 10 pipelines are expected to be at the IND-approved or IND-enabling stage, and approximately 20 are expected to reach the PCC stage. The Group's pipelines cover oncology, autoimmune diseases, metabolic diseases, chronic diseases, neurological disorders and consumer health, representing a potential market opportunity in the hundreds of billions of US dollars and offering substantial commercialization potential.

Selected Pipeline Programs at the PCC Stage or Beyond

Modality	Pipeline	Target/MoA	Indication	PCC / IND / Ph.I / Ph. II/III / Commercialization	Rights / partner	Next milestones	Remarks
Bispecific Ab	**ALX001**	TL1A/IL-23p19	Autoimmune disease		Self-developed	Ph. I in 2027	Potential BIC
Trispecific Ab	**ALX002**	CD19/BCMA/CD3	Autoimmune disease		Self-developed	Ph. I in 2027	Potential BIC
Bispecific Ab	**ALX005**	FcRn/HSA	Autoimmune disease		Self-developed	Ph. I in 2027	Potential BIC
Small molecule	**XTN004**	TRK/RET	Intestinal pain		Self-developed	China/US IND filings in 2H26	—
Small molecule	**SIGX1094**	FAK/SRC	Diffuse gastric cancer (DGC)		Signet	Ph. II in 2027	Potential FIC, Prix Galien nominee, ODD, Fast Track
Small molecule	**RTX-117**	eIF2B	Charcot–Marie–Tooth disease (CMT); vanishing white matter disease (VWM)		ReviR	Ph. II in 2027	Potential FIC, ODD
Small molecule	**PEP08**	PRMT5	Solid tumour		PharmaEngine		Potential BIC
Small molecule	**SIGX2649**	TEAD	Solid tumours (mesothelioma, liver cancer, lung cancer, etc.)		Signet	Ph. I in 2H26	Potential FIC/BIC, key data presented at 2026 AACR
Small molecule	**MP-5342**	LDH	Inflammatory bowel disease (IBD)		META	Ph. I in 2H26	Potential FIC
Small molecule	-	-	Oncology		DoveTree	IND filing in 2027	—
Cell	**META10-19**	CD19，IL-10	Relapsed/refractory CD19+ B-cell hematologic malignancy		Leman	Ph. I in 2H26	Potential BIC
Cell	**META10-19**	CD19，IL-10	Refractory B-cell autoimmune disease		Leman	Ph. I in 2H26	Potential BIC
Cell	**IL-10 GPC3 CAR-T**	GPC3，IL-10	GPC3+ liver cancer		Leman	First solid-tumour clinical data readout in 2H26	Potential BIC
Cell	**IL-10 EGFRvIII CAR-T**	EGFRvIII, IL-10	EGFRvIII+ glioma		Leman	First solid-tumour clinical data readout in 2H26	Potential BIC
Cell	**IL-10 Claudin18.2 CAR-T**	Claudin18.2, IL-10	Claudin18.2+ gastric cancer		Leman	IIT Beginning in 2H26	Potential BIC
Peptide	**Px-002C**	Single target	Glucose-lowering	FDA Self-GRAS認證	Self-developed		Consumer product
Peptide	**Px-003C**	Single target	Lipid-lowering		Self-developed		Consumer product
Peptide	**Px-001C**	Single target	Cosmetics		Self-developed	New cosmetic ingredient filing in 2H27	Consumer
Oligonucleotide	**XS01**	Single target	IgA nephropathy / PNH		Self-developed		Potential BIC

Note: This table only lists selected pipelines at PCC stage or beyond; over 20 additional pipelines are still in progress.

Small Molecules

- The Group's small-molecule R&D platform continues to evolve across key areas including AI-powered computational prediction, physics-constrained modeling, synthetic route planning and closed-loop experimental validation, forming integrated capabilities spanning molecular design, activity prediction, synthesis planning and experimental validation. Distinct from conventional physics-based computational methods, the platform's proprietary AI affinity prediction model can rapidly rank and prioritize protein–ligand binding affinity and structure–activity relationships within chemical series. Its predictive performance has approached the accuracy of gold-standard free energy perturbation (FEP) calculations, while offering higher computational efficiency, providing efficient decision support for the early-stage screening and optimization of small-molecule programs. In frontier small-molecule fields such as molecular glues, the Group has further developed XGlue™, a specialized discovery platform targeting high-value, difficult-to-drug targets. By deeply integrating AI-powered computational prediction with automated experimental validation, XGlue™ creates a rapid iterative closed loop spanning library construction, screening, synthesis, testing and optimization. The platform has established a virtual molecular glue compound library comprising millions of molecules and a physical scaffold library comprising tens of thousands of compounds. Its experimental capabilities connect automated synthesis with multidimensional testing systems, enabling the synthesis and validation of hundreds to more than 1,000 compounds per week. Experimental results are rapidly fed back into AI models to guide the next round of molecular optimization. These capabilities provide a new drug discovery path for complex targets that are difficult to address using conventional small-molecule approaches.

- **The Group has established multiple molecular glue pipelines in autoimmune** diseases and achieved significant breakthroughs. Hit compounds have been identified against multiple targets, including targets for which no molecular glues have been publicly reported. Through the integration of intelligent design and automated experimentation, **certain pipelines have achieved picomolar target protein degradation activity within approximately one quarter. The Group plans to advance the relevant programs into the preclinical stage in 2027**, while continuing to expand its autoimmune disease pipeline portfolio. If the developability and differentiated advantages of these pipelines are subsequently validated, the relevant assets may realize value through co-development or out-licensing.

- The Group has made significant progress with a proprietary small-molecule candidate targeting both TRK and RET. At the protein level, the candidate demonstrated low-nanomolar inhibitory activity against both targets, together with high selectivity and a gut-restricted profile, resulting in an excellent safety window. Intended for gut pain-related indications such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), it is the world's first candidate targeting this dual-target combination to be filed for clinical development (First-in-Class). The pipeline has completed the submission of materials for a pre-IND meeting in the United States, and the Group expects to submit IND applications in both China and the United States in the second half of 2026.

- **Multiple partnered pipelines of the Group continue to advance toward clinical development:**

  - In addition, the Phase II/III clinical trial application for SIGX1094 in combination with Innovent Biologics' approved KRAS-G12C inhibitor, fulzerasib tablets, intended for KRAS-G12C-mutated non-small cell lung cancer, has been accepted by the Center for Drug Evaluation (CDE). The Group's second pipeline program in collaboration with Signet Therapeutics, SIGX2649, a pan-TEAD inhibitor, has received IND approval in the United States and submitted an IND application to China's National Medical Products Administration (NMPA). The Group plans to initiate a Phase I clinical trial as early as the second half of 2026.

  - RTX-117, an eIF2B small-molecule activator developed by ReviR Therapeutics with the support of the Group, has received clinical trial approvals in both China and the United States for Charcot-Marie-Tooth disease (CMT), as well as clinical trial approval in China for vanishing white matter disease (VWM). A Phase I clinical trial in healthy adults is currently underway, with the Phase II clinical trial expected to commence in the first half of 2027.

- The world's first oral small-molecule inhibitor targeting lactate dehydrogenase (LDH), jointly developed with META Pharmaceuticals, has entered the IND application stage, with inflammatory bowel disease (IBD) as its lead indication.

- PEP08, a next-generation PRMT5 inhibitor developed in collaboration with PharmaEngine, has commenced patient enrollment for solid tumor indications. The parties have also initiated a second AI-driven drug discovery program targeting a novel synthetic lethality target.

- A high-value pan-cancer asset developed in collaboration with DoveTree has entered the IND stage. Preliminary validation of its biological activity demonstrated a clear target intervention effect and an excellent selectivity window. The parties will further deepen their collaboration on the agreed difficult-to-drug targets, advance R&D efforts including those involving molecular glues, and accelerate the clinical translation of drug candidates.

Large Molecules

- The Group's large-molecule platform, Ailux, is **a world-leading AI-native antibody drug development platform** and has established collaborations with multinational corporations (MNCs) across the model, platform and asset levels. Ailux's core strengths derive from the deep integration across models, data and wet-lab experimentation.

  - **Models:** Ailux is powered by three core engines, the XtalFold® structural modeling platform, XenProT® generative AI platform and Xentient® discriminative AI platform, covering the entire large-molecule R&D workflow, from structure prediction and molecular generation to functional assessment and candidate optimization. The platform has achieved significant results across a broad range of applications, including antigen design, epitope identification, affinity maturation, pH-sensitive engineering and bispecific antibody design, and has been validated by more than 100 internal and external projects.

  - **Data: AtlaX™**, the platform's proprietary **data foundation**, continuously builds a "living" database tailored to real-world drug R&D needs through proprietary wet-lab experimental systems, high-throughput data generation and the LuxSight™ patent-mining agent. Compared with public datasets, AtlaX™ offers **scaling advantages ranging from several-fold to tens-of-times** across key data types, including antibody affinity data, antigen-antibody complex structures, antigen-antibody pairing data and native heavy and light-chain sequences.

- **Wet-Lab Experimentation:** Through proprietary experimental workflows, the platform generates functional labels covering polyreactivity, stability, immunogenicity and other attributes that are difficult to capture in public datasets, creating a differentiated data moat for complex antibody drug development applications.

◦ The Group continues to strengthen the core talent team of its large-molecule platform and has appointed Dr. Maria G. Belvisi as its Chief Scientific Officer (CSO). Dr. Belvisi is a distinguished academic and industry leader in respiratory and immunology, with experience both as a senior executive at a multinational pharmaceutical company and an internationally recognized academic expert. She brings more than 30 years of experience in drug R&D and academic leadership, including approximately a decade at AstraZeneca, where she served as Senior Vice President of Respiratory and Immunology within BioPharmaceuticals R&D.

◦ In terms of pipeline progress, the Group continues to steadily advance its proprietary large-molecule assets. **Three core programs targeting autoimmune diseases are expected to enter Phase I clinical trials in 2027**, including:

- **ALX001: A bispecific antibody targeting TL1A and IL-23p19**, intended for inflammatory bowel disease indications. Through AI-driven antigen design and the identification of ultra-rare positive candidates, the program successfully identified a novel anti-TL1A mechanism with ultra-low anti-drug antibody (ADA) risk and superior activity, demonstrating the molecule's best-in-class potential.

- **ALX002: A T-cell engager targeting CD19 and BCMA**, intended for B-cell-mediated autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Its AI-driven engineering design provides the potential for a best-in-class therapeutic window by enabling potent B-cell depletion while reducing the risk of cytokine release syndrome (CRS), together with superior manufacturability. ALX002 has the potential to become a best-in-class molecule.

- **ALX005: A long-acting FcRn-blocking antibody**, intended for autoimmune diseases driven by pathogenic IgG antibodies, including myasthenia gravis and immune thrombocytopenia. Combining AI-guided epitope-focused discovery technology with XtalFold®-powered candidate screening, the program has generated a unique bispecific drug candidate with a very low safety risk. In addition, in silico viscosity prediction supports convenient subcutaneous administration, giving ALX005 the potential to become a best-in-class molecule.

Peptides

- The Group's AI peptide drug development platform, **PepiX™, integrates three core capabilities: precise AI-driven design, automated synthesis, and high-throughput wet-lab screening**, creating an efficient closed loop system between dry and wet-lab experimentation. The platform has established a proprietary database comprising **more than 5,000 non-canonical amino acids (NCAAs)**, enabling the systematic optimization of key development challenges faced by conventional peptide drugs, including stability, membrane permeability and oral bioavailability. For complex peptide molecules such as cyclic peptides and macrocycles, the platform has developed next-generation AI-based capabilities for molecular generation and 3D conformational prediction. Its core model, HELM-DIFF, can directly interpret the structural features of complex peptide molecules and generate, screen and optimize de novo candidates with high membrane permeability, favorable drug-like properties and strong target specificity. HELM-DIFF has achieved industry-leading performance in cyclic peptide membrane permeability assessment and generation tasks, significantly outperforming open-source algorithms.

- Leveraging the PepiX™ platform, the Group has successfully developed **Tensotide™, an innovative oral peptide-based food ingredient for blood glucose management, which has achieved self-affirmed Generally Recognized as Safe (GRAS) status in the United States**. This status recognizes Tensotide™ as a food-grade ingredient that is generally considered safe and may be legally used in food and dietary supplement products in the United States.

- In terms of pipeline development, the PepiX™ platform is focusing on **multiple high-potential peptide therapeutics, including brain and ocular delivery programs, and oral peptides**. The brain delivery program uses cyclic peptides as targeting moieties to deliver biological macromolecules across the blood-brain barrier. It has entered the in vivo animal testing and optimization stage and is expected to reach the preclinical candidate (PCC) stage in the first half of 2027. The oral cyclic peptide program for autoimmune indications was initiated in the first half of 2026 and identified hit compounds within two months of target selection. The program has entered the hit-to-lead stage and is expected to reach the PCC stage by mid-2027.

Small Nucleic Acid Therapeutics

- The Group's proprietary siRNA drug development platform, **Kodexia™, deeply integrates first-principles-driven biological mechanism modeling with generative AI**. Supported by a high-throughput automated experimental system, the platform has established AI-native capabilities for small nucleic acid therapeutics design and closed-loop iteration between dry and wet-lab experimentation. At the data level, Kodexia™ has accumulated tens of thousands of high-quality wet-lab data points, comprising multilevel, multimodal data across multiple cell lines and targets, spanning in vitro through in vivo studies. It has also established a diverse database of siRNA chemical modifications. At the model level, the Group has **developed its proprietary siFormer architecture**, enabling the joint design of sequences and chemical modifications. This overcomes the limitations of "fixed modification templates and limited screening" and significantly improves generalization to previously unseen targets. The platform also supports the optimization of single-molecule, dual-target siRNAs and is compatible with multiple delivery approaches, including small molecules, lipid nanoparticles (LNPs), antibodies and peptides, supporting the exploration of both hepatic and extrahepatic targeting.

- Compared with conventional approaches that rely on empirical templates and sequential trial and error, Kodexia™ uses AI-driven multi-objective prediction to transform key wet-lab experiments into highly parallel validation, significantly improving experimental throughput and decision-making efficiency. Based on publicly available comparable benchmarks, **the platform improves R&D efficiency by more than twofold compared with conventional methods and increases the accuracy of molecular property prediction by approximately 266%**. It has also established predictive capabilities for in vivo efficacy. Across multiple pipelines, **more than 50% of the molecules generated in the first round of design demonstrated greater activity than positive controls in in vivo experiments**, validating the platform's ability to accelerate the entire workflow from target to candidate molecule.

- In terms of pipeline development, Kodexia™ has enabled the Group to establish a differentiated siRNA pipeline portfolio spanning IgA nephropathy, metabolic diseases and central nervous system (CNS) disorders. **Six pipelines have been established, more than half of which have completed in vivo efficacy evaluation, with the most advanced program reaching the preclinical candidate (PCC) stage**. **The lead IgA nephropathy program generated non-human primate efficacy data within approximately seven months, demonstrating superior activity and durability compared with a clinical-stage reference molecule targeting the same target**. In the metabolic disease field, the Group is advancing both single-target and dual-target siRNA programs for weight management, aiming to achieve differentiated advantages including extended dosing intervals, healthy weight loss and broader metabolic benefits. These programs also lay the foundation for future commercialization through joint R&D, asset co-development, out-licensing and other models.

Biological Simulation Platforms

Through investments, incubation and other approaches, the Group is expanding into next-generation human-relevant experimental models, including virtual cells, human organ-on-a-chip models and organoids. These capabilities further strengthen the critical link between computational prediction and biological validation in AI-driven drug discovery (AIDD), completing the end-to-end life sciences R&D workflow. Compared with conventional cell-based experiments and animal studies, organoids and cell-on-a-chip models can more closely replicate human tissue structures, microenvironments and drug responses in vitro. This enables earlier assessment of the efficacy, safety, tissue selectivity and potential toxicity of candidate molecules, improving the ability of preclinical research to predict human responses. As regulatory systems worldwide increasingly encourage the use of more human-relevant, non-animal alternative methods, these technologies are becoming an important means of reducing costs, improving efficiency and lowering the risk of translational failure in drug R&D. By integrating AI-driven design, automated experimentation and organoid and cell-on-a-chip validation capabilities, the Group continues to expand the scope of its AIDD capabilities across target discovery, molecular design, synthesis and validation, efficacy evaluation and safety assessment, providing more comprehensive technical support for the advancement of its proprietary pipelines and external collaboration projects.

- **Virtual Cells:** OCOO-T, an AI virtual cell (AIVC) model developed by **INFevo**, a company incubated by XtalPi, achieved state-of-the-art (SOTA) performance across three perturbation benchmarks covering chemical compounds, genes and cytokines. INFevo has also launched The Popper Project (TPP), the world's first interactive, traceable and autonomously iterative scientific discovery engine, and will soon open applications for the engines closed beta testing. In the first half of 2026, INFevo completed an angel financing round, raising tens of millions of RMB, with participation from Shunwei Capital, Sequoia China and Green Pine Capital Partners.

- **Organ-on-a-Chip: Xellar Biosystems**, a company incubated by XtalPi, continues to accumulate human-derived 3D wet-lab data through its proprietary automated organ-on-a-chip production line. In parallel, it is developing a biology-focused AI foundation model and constructing a human biology atlas, creating an integrated technology and data moat spanning engineering, biology and AI. Xellar Biosystems has achieved significant progress in commercialization and industry collaborations. It successfully completed delivery of Sanofi's iDEA-TECH project and collected the final payment in full, while its joint development of an AI-powered toxicity prediction system with Pfizer achieved a key delivery milestone. In regulatory compliance, Xellar Biosystems was among the first group of companies to participate extensively in the Center for Drug Evaluation's multicenter collaborative validation of New

Approach Methodologies (NAMs) and was selected for the "Pioneer Program." It is also advancing model qualification under the U.S. Food and Drug Administration's Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. In the first half of 2026, Xellar Biosystems completed a RMB400 million Series A financing round, with its Series B financing also progressing as planned.

- **Organoids:** The organoid and AI platform jointly developed by XtalPi and **Signet Therapeutics** has established a standardized system comprising more than 15 genetically engineered tumor organoid models, including models for diffuse gastric cancer, liver cancer and lung cancer, for use in drug development. Beyond oncology pipelines, the platform has combined AI with normal organoids of the heart, kidney and liver to establish highly accurate drug toxicity prediction and evaluation models. Its cardiac organoid-based drug toxicity prediction model achieved an accuracy of 81.25%, significantly exceeding the 43.75% accuracy of conventional methods. As the only early-stage pharmaceutical company participating, Signet Therapeutics' organoid platform has been extensively involved in the national organoid standards project led by the Center for Drug Evaluation (CDE) and the Innovation Method Evaluation Center of China's National Institutes for Food and Drug Control. It continues to advance methodological validation for organoids, the development of relevant guidelines and the large-scale commercial adoption of organoids as alternatives to conventional biological models.

3.1.2 Key Commercialization Progress: Major Collaborations Secured in Rapid Succession, with Increasingly Diversified Monetization Models

- **The Group entered into a strategic collaboration for AI-driven drug discovery, with a total potential value exceeding USD400 million, with a renowned international biopharmaceutical company that has a robust pipeline and multiple commercial products.** The parties will jointly develop an innovative oral small-molecule drug with best-in-class potential against a G protein-coupled receptor (GPCR) target. The collaboration partner will make an upfront payment and fund all early-stage R&D costs. The Group will also be eligible to receive preclinical, clinical and commercialization milestone payments, as well as royalties on future sales, with the total potential value of the project exceeding USD400 million.

- **The Group entered into a key collaboration with Visen Pharmaceuticals.** The parties will integrate XtalPi's AI-driven robotic drug discovery platform with Visen Pharmaceuticals' expertise in endocrinology, focusing on high-value clinical indications and innovative targets in endocrinology and metabolism to jointly advance the early discovery and clinical development of innovative therapies. The overall scale of this collaboration amounts to tens of millions of RMB.

- **The Group signed a landmark strategic collaboration agreement with Sunshine Lake Pharma.** The parties intend to establish a joint venture that will combine the industry-leading capabilities of XtalPi's AI-driven robotic drug discovery platform with Sunshine Lake Pharma's extensive multi-target R&D data, biological insights and pipeline development experience. Through the joint establishment of an AI-driven robotic laboratory and a foundation model for preclinical drug development, the parties aim to address longstanding challenges in drug R&D and pursue comprehensive collaboration spanning underlying technologies, innovative drug pipeline development and commercialization. Sunshine Lake Pharma is expected to invest several hundreds of millions of RMB in the collaboration. The two companies aim to build an industry-leading AI drug discovery engine and bring the technology to international markets, while developing a diversified monetization model centered on "pipeline co-creation and shared success through technology."

- **The Group's collaboration with DoveTree has progressed well, and the Group has received the second payment of USD19.0 million as stipulated under the definitive agreement**. The parties will further deepen their collaboration in the agreed difficult-to-drug target areas, advance R&D efforts including those involving molecular glues, and continue to accelerate the translation of drug candidates toward clinical development.

- **In November 2025, the Group entered into a global strategic collaboration and platform licensing agreement with Gan & Lee Pharmaceuticals for AI-driven innovative peptide drug R&D, and the project is progressing smoothly. This year, the "AI-Driven Intelligent Peptide Delivery Laboratory" (Beijing Key Laboratory of Artificial Intelligence for Peptide Drug Design and Delivery Systems), jointly established by the parties, was officially recognized as a Beijing Key Laboratory and formally inaugurated**. This marks a new phase of deeper collaboration between the parties in AI-enabled peptide drug R&D and further demonstrates the continued industry adoption and scalable application potential of XtalPi's AI peptide development platform, PepiX™.

3.2 AI4S Intelligent Solutions: AI4S Platform's Value Creation Accelerating, Driving Breakthrough Revenue Growth

During the Reporting Period, AI4S Intelligent Solutions generated revenues of RMB193.5 million, representing a year-on-year increase of 136.4%, with both AI4S Intelligent Robotic Laboratories (Physical AI) and AI4S Intelligent Services maintaining significant growth. Amid continued momentum across the AI4S industry, growth in AI4S Intelligent Robotic Laboratories (Physical AI) was primarily driven by the accelerated adoption of an emerging industry consensus: using robotic laboratories to build a data foundation and feed high-quality data back into AI models. Growth in AI4S Intelligent Services was mainly driven by the increasingly urgent need for AI-driven drug R&D to explore broader chemical space and shorten development cycles. The Group's innovative molecular building blocks and VAST Virtual Compound Library enables customers to expand their exploration of chemical space, while its high-throughput autonomous synthesis platform creates an efficient closed-loop system spanning "design, synthesis, testing and analysis," significantly accelerating the commercialization of AI4S Intelligent Services. As one of the first companies in the industry to establish a closed loop system connecting the digital and physical worlds, the Group has leveraged its difficult-to-replicate technological barriers to define and create this new category of industry demand, further strengthening its leading position in AI4S.

3.2.1 AI4S Intelligent Robotic Laboratories (Physical AI): Embedded into Molecular R&D Workflows to Drive Scalable Growth

Under the AI4S paradigm, high-quality data is a core input driving the iterative improvement of AI models and their predictive capabilities. Through standardized experimental workflows and high-throughput parallel operations, intelligent robotic laboratories can systematically generate high-quality, reproducible and traceable experimental data, fundamentally addressing the limitations of conventional R&D models, including inefficient data generation, inconsistent data quality and difficulties in accumulating reusable assets that can then be considered proprietary institutional knowledge. Amid continued momentum across the global AI4S industry, downstream customers are significantly increasing their investment in intelligent R&D infrastructure. A virtuous cycle, namely using intelligent robotic laboratories to build the data foundation, feeding high-quality data back into the AI models and using improved models to guide subsequent rounds of experimentation, is becoming an industry consensus and gaining adoption at an accelerating pace.

During the Reporting Period, the Group's AI4S Intelligent Robotic Laboratory business made positive progress in both overseas and domestic markets. In overseas markets, **the compound management system developed in collaboration with Eli Lilly was successfully contracted and delivered, while the first HTE system completed factory acceptance testing (FAT) and user training. The intelligent autonomous drug synthesis and process R&D system developed in collaboration with JW Pharmaceutical was fully delivered in April and received strong recognition from the customer.** In the domestic market, the Group continued to deepen its scientific research collaboration and secured multiple projects valued at tens of millions of RMB. In addition, **the intelligent synthesis workstation, a semi-standardized product, has been successfully replicated and deployed across 13 customers**, further validating its productization capabilities. Leveraging the reusability of the same underlying Physical Agent and Agent orchestration platform, **these capabilities have expanded beyond pharmaceuticals into advanced materials fields, including perovskites, lithium batteries and molecular sieves.**

During the Reporting Period, the Group's AI4S Intelligent Robotic Laboratory business **successfully delivered multiple flagship projects**:

- **The Group signed an eight-figure RMB compound storage and management system project with Eli Lilly** and completed delivery to their Shanghai R&D center. The system covers the complete compound workflow, from storage and retrieval through micro-scale powder dispensing and the preparation and output of samples in DMSO solution. It integrates previously separate sample management and preparation processes into a unified automated platform, providing increased continuous and standardized sample-handling capabilities for drug R&D experiments. The system significantly improves compound storage and retrieval efficiency and sorting accuracy, while enabling the customer to accumulate high-quality, structured compound data assets to support its growing R&D pipeline needs.

- **The Group signed an eight-figure RMB collaboration project with Eli Lilly for a high-throughput experimentation (HTE) platform.** Centered on a condition-screening glovebox, the newly designed modular platform supports automated reagent dispensing, reactions, dilution and filtration under anhydrous and oxygen-free conditions, and is integrated with XtalPi's Agentic AI algorithms. The platform will enable the customer to significantly increase the throughput and efficiency of condition screening, shorten the design–make–test–analyze (DMTA) cycle from molecular design through synthesis and validation, and generate standardized, traceable experimental data. This will support the accumulation of high-quality data assets for AI model training and algorithm optimization. Following the compound storage and management project, this represents another in-depth collaboration between the parties in laboratory automation. This marks the expansion

of the collaboration from the "intelligent management of compound assets" to the "end-to-end automation of synthesis and screening," further deepening the partnership.

- **The high-throughput automated synthesis workstation, AI-powered reaction condition optimization system and intelligent analytics platform provided by the Group to JW Pharmaceutical were fully delivered in April** and received strong recognition from the customer. The platform addresses JW Pharmaceutical's complex R&D needs in the automated screening and synthesis of drug candidates and process optimization. By integrating Bayesian optimization, digital management and automated laboratory technologies, the solution is expected to improve the success rate and reproducibility of chemical synthesis and shorten drug development cycles. It provides a robust technological foundation for JW Pharmaceutical's development of breakthrough pipelines in oncology, metabolic diseases and other fields, helping advance competitive drug candidates into clinical research at an earlier stage.

- **The Group signed a millions-of-RMB intelligent high-throughput mesoporous materials preparation project with the Wusong Materials Laboratory of Fudan University.** Supported by Fudan University's newly established School of Intelligent Materials and Future Energy Innovation, the project will build a fully automated laboratory dedicated to mesoporous materials, enabling integrated R&D spanning preparation, synthesis and characterization. With their high specific surface area, ordered pore structures and tunable pore sizes, mesoporous materials have broad application potential in fields including catalysis, adsorption and separation, and energy storage, and are a major focus of advanced materials research. Conventional mesoporous materials R&D relies on manual trial and error, involving numerous parameters and lengthy optimization cycles. By combining an automated high-throughput platform with AI-driven experimental design, the project can significantly improve materials R&D efficiency and shorten the timeline for laboratory research to industrialization.

- **The Group signed a millions-of-RMB end-to-end perovskite solar cell automation project with a leading university.** The Group will provide the customer with a fully automated solution covering the entire perovskite solar cell R&D workflow. The project addresses the key challenges associated with linking multiple post-film-formation processes and manually transferring samples between them. It comprises five core modules: a sample transfer module, vapor deposition module 1, a laser P2 module, vapor deposition module 2 and a current density-voltage (J-V) testing module. Together, these modules enable end-to-end automation spanning sample transfer, organic- and metal-layer deposition, laser edge isolation and J-V electrical performance testing. Once implemented, the project is expected to significantly improve

experimental efficiency and data consistency. It will also represent XtalPi's first deployed case in the perovskite field and provide strong academic validation, establishing a replicable benchmark for the Group's expansion in perovskite solar cell R&D automation.

- **The Group signed a millions-of-RMB project with Peking University, the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences and other institutions to develop a high-throughput automated electrolyte formulation and testing platform.** The project will provide customers with a high-throughput automated solution for formulating lithium-ion and sodium-ion battery electrolytes and testing their key physicochemical properties. The project addresses key challenges in electrolyte R&D, including stringent solid-to-liquid ratio requirements, difficulties in maintaining batch-to-batch consistency and low efficiency during manual testing. It comprises five core modules: a solid and liquid dispensing and reaction station, a liquid dispensing module, an automated storage and transfer system, a cap opening and closing and visual positioning module, and a key performance testing module. Together, these modules enable end-to-end automation spanning solid and liquid weighing, mixing and formulation, shaking and temperature control, and conductivity and moisture testing. Once implemented, the project is expected to significantly improve electrolyte formulation efficiency and batch-to-batch consistency. It also enables the Group to establish an early presence in a high-growth segment with relatively limited competition and strong customer budgets, providing a replicable benchmark for XtalPi's expansion in battery electrolyte R&D automation.

3.2.2 AI4S Intelligent Services: A Key Breakthrough in End-to-End Autonomous AI Decision-Making, Driving Rapid Order Growth

As the commercialization of AI4S accelerates, pharmaceuticals R&D is rapidly shifting from a conventional trial-and-error approach towards a data-driven, intelligent framework, while customer demand for broader chemical space exploration and shorter R&D cycles is growing significantly. The Group's AI4S Intelligent Services directly address these core customer needs in two ways. First, the Group provides innovative molecular building blocks and the VAST Virtual Compound Library, enabling customers to efficiently explore a broader chemical universe and significantly increase the probability of discovering novel lead compounds. Second, the Group has established a high-throughput autonomous synthesis platform that enables rapid validation from molecular design through physical synthesis, creating an efficient design–make–test–analyze (DMTA) closed loop system.

During the Reporting Period, the combined strength of these capabilities significantly accelerated the commercialization of the Group's AI4S Intelligent Services. The value of new orders signed in the first half of 2026 recorded significant growth, demonstrating strong market demand and customer recognition for the Group. Notably, the newly launched VAST Virtual Compound Library business achieved a significant breakthrough, securing orders covering more than 20,000 molecules and creating a new source of incremental revenue growth for the Group.

During the Reporting Period, **the Group developed and commercialized two major solutions – Agentic Synthesis (Intelligent Autonomous Molecular Synthesis) and Agentic HTE (Intelligent Autonomous High-Throughput Experimentation) – enabling end-to-end autonomous AI decision-making.**

- *Agentic Synthesis Solution (Intelligent Autonomous Molecular Synthesis)*

  Agentic Synthesis is the Group's proprietary autonomous synthesis platform, centered on an Agentic System that connects Scientific AI with Physical AI. The platform creates an end-to-end, ten-step closed loop that spans molecule targeting through final product delivery. Chemists need only describe the target molecule and the required number of reaction conditions in natural language, after which the system can autonomously complete the entire workflow, including raw materials receipt verification, experimental record creation, AI-powered condition generation, automated reagent dispensing, reaction monitoring, purification, quality control and delivery. This frees chemists from labor-intensive experimental tasks, allowing them to focus on core decision-making and professional judgment.

  In developing the Group's Scientific AI capabilities, all four core modules have achieved production-grade accuracy. **The SureRXN™ synthesizability prediction and condition recommendation module achieved an experimental success rate of over 90%, reducing the average number of experiments to 1.19. The high-pressure separation algorithm achieved an automation rate of 76%, while increasing the first-delivery success rate from 83% to 94%. The LCMS spectral analysis algorithm achieved an overall prediction accuracy of 95%, rising to 98% within the high-confidence range. The NMR spectral interpretation algorithm automatically analyzed more than 70% of spectra across four projects, demonstrating continued improvement.**

At the Agentic System level, seven dedicated agents form a complete "digital chemistry team": the PM Agent for project coordination; the Experiment Agent for experiment initiation and scheduling; the IPC Agent for determining reaction success or failure through LCMS analysis; the Purification Agent for tracking purification work orders; the QC Agent for quality control and structural confirmation; the Delivery Agent for delivery packaging; and the Procurement Agent for monitoring raw materials receipts and low-inventory alerts. Each agent corresponds to a real-world business role, and together they cover the entire project lifecycle from initiation through shipment. Building on this foundation, the platform enables a complete ten-step operational workflow: target molecule confirmation, building block (BB) procurement, reaction route design, reaction initiation and monitoring, workup, separation and preparative purification, lyophilization, quality control, final product shipment, and overall analysis and review. All stages operate continuously in a closed loop. Each step clearly identifies the respective roles of Scientific AI, the Agentic System and Physical AI, ensuring that the entire process is auditable, reviewable and continuously iterative.

- *Agentic HTE Solution (Intelligent Autonomous High-Throughput Experimentation System for Reaction Condition Optimization)*

  Agentic HTE is an end-to-end high-throughput experimentation solution centered on an Agentic System that connects Scientific AI with Physical AI. Through its core capabilities including intent understanding, skill orchestration, long-running task management and human–AI collaboration, the solution **substantially shortens the conventional HTE iteration cycle from three to four weeks to approximately six days**, significantly expanding the efficiency of high-throughput experimentation. It represents another flagship product developed by the Group in the field of AI-driven laboratory automation.

  While strengthening its end-to-end autonomous AI decision-making capabilities, the Group is also actively expanding its capabilities in upstream chemical space design and synthesis. In June 2025, XtalPi completed the acquisition of Liverpool ChiroChem (LCC). LCC has long focused on developing technologies for the design and synthesis of novel molecules, particularly novel chiral molecules. Its PACE (Parallel Automated Chiral Engine) technology platform integrates AI software with automation technologies, enabling the virtual screening of target molecules from a chiral chemical library comprising hundreds of millions of molecules, followed by efficient automated synthesis and physical testing. **The platform has been validated through the Group's internal drug discovery projects, rapidly generating novel active compounds against a range of highly challenging targets. LCC is currently in late-stage discussions with major pharmaceutical companies, biotechnology companies and leading**

research institutions regarding collaborations centered on the PACE platform, with the aim of accelerating the creation of intellectual property and assets against partners' high-priority targets.

3.3 Advanced Materials and Consumer Health: AI4S Capabilities Broadening Applications, with Key Milestones Achieved

Building on the systematic validation of the Group's proprietary AI-driven R&D closed loop (comprising Scientific AI, Physical AI and Agentic Systems) in drug discovery and development, the Group is leveraging its core capabilities across industries and accelerating their application in emerging areas such as advanced materials and consumer health. This marks a strategic evolution from deep industry specialization to a scalable platform model, with the broader value of the Group's underlying AI4S infrastructure gradually being realized.

- ***Advanced Materials: Intelligent R&D Platform Empowers Materials Innovation, Driving Breakthrough Progress in Perovskite Tandem Cell R&D***

  Advanced materials serve as a critical foundation for sectors including new energy, advanced manufacturing and electronics, offering substantial long-term market potential and clear growth prospects. The Group has established an advanced materials R&D team and, by applying its generalizable design–make–test–analyze (DMTA) closed-loop R&D platform, has achieved substantive breakthroughs across multiple frontier materials fields. It is collaborating with leading photovoltaic company JinkoSolar to build an automated production line for the development of advanced materials used in perovskite tandem solar cells, with continuous iteration aimed at improving photoelectric conversion efficiency and cell stability. The Group has also expanded into polymer composite materials R&D, further broadening the scope of its advanced materials business.

  Perovskite Materials Progress

  During the Reporting Period, the Group entered into a strategic collaboration agreement with a subsidiary of JinkoSolar to advance AI- and automation-driven high-throughput R&D for tandem solar cells. The parties have established a joint venture to build the world's first fully closed-loop intelligent manufacturing line for tandem solar cells, integrating "AI-driven decision-making, robotic execution and data feedback" to develop high-efficiency, high-stability solar cell products for diverse application scenarios. The project is progressing smoothly.

In addition, XtalPi has established an AI- and automated laboratory-driven perovskite formulation R&D platform integrating literature data mining, specialized database development, AI model-powered parameter recommendations and automated experimental validation. In terms of device performance, small-area modules achieved a laboratory-tested efficiency of 27.0% and a third-party-certified efficiency of 26.51%, while large-area modules achieved a laboratory-tested efficiency of 23.0% and a third-party-certified efficiency of 22.74%. The robotic experimentation system has also completed the preparation of a large number of cell samples, while a high-throughput automated production line for tandem solar cells is being established with a designed daily throughput of no fewer than 1,000 cells. **Compared with conventional manual R&D processes, the optimization cycle for each iteration has been reduced from several months to several hours, while the overall R&D cycle has been shortened from four-to-six years to one-to-six months, representing a multiple order-of-magnitude leap in R&D efficiency.**

- ***Groland Expands Omnichannel Reach, Advancing Commercialization***

  During the Reporting Period, Groland, whose products contain a combination formulation incorporating two proprietary topical molecules developed by XtalPi to address hair growth and retention, completed its initial market validation and continues to progress brand development. Positioned around technology-driven scalp care, Groland has begun to build a comprehensive marketing network spanning domestic and international markets and online and offline channels. Online, the brand operates official stores on Tmall, JD.com and Douyin. Groland's AquaKine Scalp Serum achieved a No. 1 ranking on Tmall's "New Anti-Hair Loss Scalp Oil Products" chart, while its Tmall store ranked among the top three emerging personal care stores by gross merchandise value during the 618 Shopping Festival. The brand has established a comprehensive product portfolio spanning **pre-shampoo treatments, shampoos, conditioners, leave-in treatments, hair growth serums and red-light hair growth brushes. The Group's two proprietary molecules have completed regulatory filings as new cosmetic ingredients in China, while the regulatory filings and launch of the general-trade versions are expected to be completed by the end of 2026.**

4. STRATEGIC PROGRESSION: EVOLVING XTALPI SCIENCE INTO AN OPEN SCIENTIFIC AI INFRASTRUCTURE PLATFORM

In July 2026, the Group officially launched XtalPi Science, its Scientific AI platform, together with its Genius Agent suite of Scientific Agents. XtalPi Science is the world's first comprehensive AI4S platform integrating large language models (LLMs), Scientific Agents and large-scale automated wet-lab capabilities. The platform further standardizes and productizes the Group's integrated scientific research infrastructure, which has been developed over many years and validated through the completion of real-world projects. It transforms this infrastructure into a solution that can be accessed through a unified interface, orchestrated on-demand and continuously expanded. In doing so, XtalPi Science is progressively building a Global Scientific Utility for industry partners and research institutions worldwide, lowering the barriers to accessing advanced scientific R&D capabilities and providing a unified gateway for cross-institutional R&D collaboration and the scaled adoption of Scientific AI.

As the core orchestration hub and R&D matrix of the overall system, Genius Agent establishes a multi-agent system that combines global planning with scenario-specific execution capabilities. It can autonomously understand complex scientific research objectives, break down and advance long-horizon interdisciplinary tasks, and centrally orchestrate domain-specific models, specialized tools, R&D workflows and physical execution infrastructure. Under the unified orchestration of Genius Agent, the platform can generate scientific hypotheses and perform specialized predictions in the digital world, followed by high-precision experimental validation in the physical world through Physical AI. The experimental results then inform subsequent predictions and decisions, completing a closed loop spanning "digital hypothesis generation, specialized prediction, physical validation and data feedback." This transforms scientific research from a process reliant on fragmented tools and manual handoffs into a systematic workflow that is orchestratable, verifiable, traceable and continuously iterative, advancing AI from hypothesis generation to validation.

The development of open Scientific AI infrastructure depends on connecting and coordinating diverse specialized capabilities. The Group and 26 partners jointly launched the Open Ecosystem Alliance for Scientific AI, whose members span multiple segments of the scientific innovation value chain. The launch marks a new stage in the development of Scientific AI infrastructure, moving beyond individual corporate initiatives toward collaborative development across industries, disciplines and multiple stakeholders. XtalPi Science also plans to introduce Science Token as a unified access and metering mechanism for scientific research resources, improving the efficiency of resource allocation, utilization and management. Taking into account customers' actual needs and different R&D scenarios, the Group will flexibly explore diverse platform service and collaboration models as it continues to evolve into an open Scientific AI infrastructure platform.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Note	For the six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenues	*2*	**393,627**	517,076
Cost of revenues	*3*	**(167,834)**	(81,959)
General and administrative expenses	*3*	**(212,142)**	(200,333)
Research and development expenses	*3*	**(367,838)**	(221,527)
Selling and marketing expenses	*3*	**(48,000)**	(40,354)
Impairment losses on financial assets		**(1,061)**	(8,523)
Other income		**13,335**	30,646
Other gains, net	*4*	**135,673**	37,702
Operating (loss)/profit		**(254,240)**	32,728
Finance income		**91,230**	51,874
Finance expenses		**(60,125)**	(3,654)
Finance income, net		**31,105**	48,220
Impairment loss on investments accounted for using equity method		**–**	(2,348)
Share of net losses of investments accounted for using equity method		**(1,179)**	(2,991)
(Loss)/profit before income tax		**(224,314)**	75,609
Income tax expense	*5*	**(630)**	–
(Loss)/profit for the period		**(224,944)**	75,609
(Loss)/profit for the period attributable to:			
Equity holders of the Company		**(251,901)**	82,795
Non-controlling interests		**26,957**	(7,186)
		(224,944)	75,609
		RMB Cent	*RMB Cent*
(Loss)/earnings per share for (loss)/profit attributable to equity holders of the Company			
Basic (loss)/earnings per share	*6*	**(6)**	2
Diluted (loss)/earnings per share	*6*	**(6)**	2

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Note	For the six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
(Loss)/profit for the period		**(224,944)**	75,609
Other comprehensive (loss)/income			
Items that will not be reclassified to profit or loss			
– Currency translation differences		**(414,690)**	(69,110)
Items that may be subsequently reclassified to profit or loss			
– Currency translation differences		**153,082**	26,619
Other comprehensive loss for the period, net of tax		**(261,608)**	(42,491)
Total comprehensive (loss)/income for the period, net of tax		**(486,552)**	33,118
Total comprehensive (loss)/income for the period attributable to:			
Equity holders of the Company		**(511,643)**	40,455
Non-controlling interest		**25,091**	(7,337)
		(486,552)	33,118

CONDENSED CONSOLIDATED BALANCE SHEET

	Note	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Assets			
Non-current assets			
Property, plant and equipment		**263,886**	269,452
Right-of-use assets		**128,721**	95,170
Intangible assets		**232,265**	233,390
Investments accounted for using the equity method		**158,826**	42,855
Financial assets at fair value through profit or loss		**2,521,587**	2,096,127
Prepayments		**25,331**	6,922
Trade receivables	*8*	**6,933**	6,793
		3,337,549	2,750,709
Current assets			
Inventories		**275,161**	127,424
Trade and note receivables	*8*	**209,513**	151,149
Contract assets		**3,586**	3,586
Prepayments, deposits and other receivables		**126,434**	116,004
Financial assets at fair value through profit or loss		**2,197,960**	2,566,406
Restricted cash		**5,022**	17,990
Bank deposits		**3,845,317**	1,911,128
Cash and cash equivalents		**2,622,881**	2,573,066
		9,285,874	7,466,753
Total assets		**12,623,423**	10,217,462
Equity			
Equity attributable to equity holders of the Company			
Share capital		**301**	301
Other reserves		**17,700,016**	17,831,800
Accumulated losses		**(8,700,315)**	(8,448,414)
		9,000,002	9,383,687
Non-controlling interests		**72,256**	47,165
Total equity		**9,072,258**	9,430,852

	Note	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Liabilities			
Non-current liabilities			
Long-term bank borrowings		**270,500**	175,000
Lease liabilities		**90,436**	70,596
Deferred government grants		**24,162**	28,004
Deferred tax liabilities		**7,242**	7,448
		392,340	281,048
Current liabilities			
Trade and note payables	*9*	**129,989**	62,282
Other payables and accruals		**183,416**	185,509
Short-term borrowings		**2,719,930**	170,800
Derivative financial instruments		**–**	4,137
Deferred government grants		**3,299**	2,733
Contract liabilities		**84,571**	54,639
Lease liabilities		**37,620**	25,462
		3,158,825	505,562
Total liabilities		**3,551,165**	786,610
Total equity and liabilities		**12,623,423**	10,217,462

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cash flows from operating activities		
Net cash used in operating activities	**(399,238)**	(238,479)
Cash flows from investing activities		
Interest received from bank deposits	**29,418**	1,150
Payments for purchase of property, plant and equipment	**(49,787)**	(31,686)
Proceeds from disposal of property, plant and equipment	**77**	25
Payments for purchase of intangible assets	**(18,659)**	(5,162)
Payments for additions of investments accounted for using equity method	**(91,200)**	(22,064)
Payments for acquisition of investments in financial assets at fair value through profit or loss	**(1,372,644)**	(1,514,344)
Proceeds from disposal of financial assets at fair value through profit or loss	**1,320,602**	933,600
Settlement of derivative financial instruments	**(8,794)**	3,823
Payments for acquisition of assets	**–**	(3,760)
Payment for acquisition of a subsidiary, net of cash acquired	**–**	(98,816)
Placement of bank deposits	**(3,425,082)**	(1,073,683)
Prepayment for an equity interest investment	**–**	(6,085)
Proceeds from maturity of bank deposits	**1,421,320**	105,588
Changes in restricted cash balances	**12,968**	(1,768)
Proceeds from government grants	**894**	1,080
Net cash used in investing activities	**(2,180,887)**	(1,712,102)
Cash flows from financing activities		
Interest paid for bank borrowings	**(5,071)**	(1,980)
Payments of lease liabilities	**(17,086)**	(14,259)
Proceeds from issuance of ordinary shares, net of underwriting commissions	**–**	2,901,350
Proceeds from issuance of convertible bonds, net of transaction cost	**2,512,330**	–
Proceeds from exercise of share options	**2,338**	3,757
Proceeds from bank borrowings	**338,900**	258,930
Repayments of bank borrowings	**(154,600)**	(29,900)
Net cash generated from financing activities	**2,676,811**	3,117,898
Net increase in cash and cash equivalents	**96,686**	1,167,317
Cash and cash equivalents at beginning of the period	**2,573,066**	1,166,148
Effects of exchange rate changes on cash and cash equivalents	**(46,871)**	(21,777)
Cash and cash equivalents at end of the period	**2,622,881**	2,311,688

NOTES

1. BASIS OF PREPARATION

This condensed consolidated interim financial information of the Group for the six months ended 30 June 2026 (the "**Interim Financial Information**") has been prepared in accordance with International Accounting Standard ("**IAS**") 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("**IASB**").

The Interim Financial Information does not include all the notes of the type normally included in annual financial statements. Accordingly, this Interim Financial Information should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2025, which have been prepared in accordance with IFRS Accounting Standards issued by the IASB.

The preparation of the Interim Financial Information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates. In preparing this Interim Financial Information, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty are consistent with those applied in the consolidated financial statements for the year ended 31 December 2025.

1.1 Accounting policy information

(a) Amendments to standards adopted by the Group

The following amendments to standards have been adopted by the Group for the financial year beginning on 1 January 2026:

Amendments to IFRS 9 and IFRS 7	Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Annual Improvements to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards – Volume 11

The adoption of above amended standards does not have any significant impact on the consolidated financial statements of the Group.

(b) Amendments to standards and new standards not yet adopted

Amendments to standards and new standards that have been issued but are not yet effective and not been early adopted by the Group for the financial year beginning on 1 January 2026 are as follows:

		Effective for accounting periods beginning on or after
Amendments to IAS 21	Translation to a Hyperinflationary Presentation Currency	1 January 2027
IFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
IFRS 19	Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to Illustrative Examples on IFRS 7, IFRS 18, IAS 1, IAS 8, IAS 36 and IAS 37	Disclosures about Uncertainties in the Financial Statements	To be determined
IFRS 10 and IAS 28 (Amendments)	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

The directors have performed assessment on the above new and amendments to standards, and have concluded on a preliminary basis that these new and amendments to standards would not have a significant impact on the Group's consolidated financial statements when they become effective, except for IFRS 18 which will impact the presentation of profit and loss and result in additional disclosure in the consolidated financial statements. The Group is currently assessing the detailed implications of applying the new standard on the Group's consolidated financial statements. From the high-level preliminary assessment performed, the following potential impacts have been identified:

- Although the adoption of IFRS 18 will have no impact on the Group's net profit, the Group expects that grouping items of income and expenses in the statement of profit or loss into the new categories will impact how operating profit is calculated and reported.

- The line items presented on the primary financial statements might change as a result of the application of the concept of 'useful structured summary' and the enhanced principles on aggregation and disaggregation. In addition, since goodwill will be required to be separately presented in the statement of financial position, the Group will disaggregate goodwill and other intangible assets and present them separately in the statement of financial position.

- The Group does not expect there to be a significant change in the information that is currently disclosed in the notes because the requirement to disclose material information remains unchanged; however, the way in which the information is grouped might change as a result of the aggregation/disaggregation principles. In addition, there will be significant new disclosures required for:

  – management-defined performance measures;

  – a break-down of the nature of expenses for line items presented by function in the operating category of the statement of profit or loss – this break-down is only required for certain nature of expenses; and

  – for the first annual period of application of IFRS 18, a reconciliation for each line item in the statement of profit or loss between the restated amounts presented by applying IFRS 18 and the amounts previously presented applying IAS 1.

- From a cash flow statement perspective, there will be changes to how interest received and interest paid are presented. Interest paid will be presented as financing cash flows and interest received as investing cash flows, which is a change from current presentation as part of operating cash flows.

(c) Accounting policies not included in the Group's annual financial statements for the year ended 31 December 2025

Financial liabilities

(i) Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables, derivative financial instruments, lease liabilities, interest-bearing borrowings and debt component of convertible bonds.

(ii) Subsequent measurement

The subsequent measurement of financial liabilities depends on their classification as follows:

Financial liabilities at amortised cost

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in the statement of profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance costs in the statement of profit or loss.

(iii) Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in the statement of profit or loss.

(iv) Convertible bonds

The component parts of the convertible bonds are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument. Transaction cost that relates to the issue of the convertible bonds are allocated to the financial liability and equity instrument in proportion to their relative fair values.

At the date of issue of the convertible bonds, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date.

The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the convertible bonds as a whole. This is recognised and included in equity, net of income tax effects, and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity when the conversion option is exercised.

2. REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue disaggregated by revenue source as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Drug discovery solutions	**200,109**	435,212
AI for Science intelligent solutions	**193,518**	81,864
	393,627	517,076
Timing of revenue recognition:		
A point in time	**345,375**	473,275
Over time	**48,252**	43,801
	393,627	517,076

Revenue from external customers contributing over 10% to the total revenue of the Group for the six months ended 30 June 2026 and 2025 are as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**129,407**	365,089

Revenue disaggregated by geography, based on the billing address of the customers is as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Chinese Mainland	**158,562**	79,451
United States	**184,385**	413,311
Other regions	**50,680**	24,314
	393,627	517,076

3. EXPENSES BY NATURE

Expenses included in cost of revenues, general and administrative expenses, research and development expenses and selling and marketing expenses are analysed as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefit expenses	**451,848**	316,832
Material costs	**120,295**	42,048
Professional service fees	**67,180**	43,912
Depreciation of property, plant and equipment	**40,051**	38,615
Cloud service and IT infrastructure expenses	**31,616**	13,291
Depreciation of right-of-use assets	**19,456**	14,123
Amortisation of intangible assets	**7,482**	3,305
Short-term rental expenses	**6,117**	7,116
Impairment provision on property, plant and equipment	**2,266**	28,123
Others	**49,503**	36,808
	795,814	544,173

4. OTHER GAINS, NET

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Net foreign exchange (losses)/gains	**(18,734)**	3,820
(Losses)/gains on derivative financial instruments	**(4,720)**	3,823
Net fair value changes on financial assets measured at FVTPL	**154,242**	34,438
Donations	**–**	(5,758)
Others	**4,885**	1,379
	135,673	37,702

5. INCOME TAX EXPENSE

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax	**836**	–
Deferred income tax	**(206)**	–
	630	–

The Group's principal applicable taxes and tax rates are as follows:

Cayman Islands

The Company and certain subsidiaries that were incorporated in the Cayman Islands as exempted companies with limited liability under the Companies Law of the Cayman Islands are not subject to the Cayman Islands income tax pursuant to the current laws of the Cayman Islands.

Hong Kong

The subsidiaries in Hong Kong are subject to Hong Kong profit tax at a rate of 16.5% during the six months ended 30 June 2026 and 2025.

PRC

The Group's subsidiaries established in the PRC are generally subject to Corporate Income Tax at a rate of 25% on the estimated assessable profit in accordance with relevant PRC income tax laws and certain preferential tax treatments available to certain subsidiaries during the six months ended 30 June 2026 and 2025.

Shenzhen Jingtai Technology Co., Ltd., Beijing Jingtai Technology Co., Ltd., Jingtai Zhiyao Technology (Shanghai) Co., Ltd. and Shanghai Siwei Medical Technology Co., Ltd. were approved as "High and New Technology Enterprise" and entitled to a preferential income tax rate of 15% during the period ended 30 June 2026. There are certain other subsidiaries of the Group in the PRC that have been granted certain tax concessions for small scale entities by tax authorities in the PRC and enjoy reduced tax rates.

United States

The subsidiaries in the United States are subject to Federal Tax at a rate of 21% and State Tax at a rate of 8% to 8.84%.

6. BASIC AND DILUTED (LOSS)/EARNINGS PER SHARE

(a) Basic (loss)/earnings per share

Basic (loss)/earnings per share for the six months ended 30 June 2026 and 2025 are calculated by dividing the (loss)/profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the respective period (excluding the treasury shares held for the Pre-IPO Share Incentive Plan).

	For the six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
(Loss)/profit attributable to equity holders of the Company *(RMB'000)*	**(251,901)**	82,795
Weighted average number of ordinary shares in issue *(thousand shares)*	**4,083,861**	3,595,629
Basic (loss)/earnings per share *(expressed in RMB cent per share)*	**(6)**	2

(b) Diluted (loss)/earnings per share

Diluted (loss)/earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. The Company has three categories of dilutive potential ordinary share being (1) share options; (2) awarded shares granted by the Company; and (3) convertible bonds.

	For the six months ended 30 June 2025 (Unaudited)
Profit attributable to equity holders of the Company *(RMB'000)*	82,795
Weighted average number of ordinary shares in issue *(thousand shares)*	3,595,629
Adjustments for share options and share awards *(thousand shares)*	166,075
Weighted average number of ordinary shares for the calculation of diluted EPS *(thousand shares)*	3,761,704
Diluted earnings per share *(expressed in RMB cent per share)*	2

Diluted loss per share presented is the same as basic loss per share as the inclusion of the potential ordinary shares in the calculation of dilutive loss per share would be anti-dilutive for the six months ended 30 June 2026.

7. DIVIDENDS

No dividends have been paid or declared by the Company for the six months ended 30 June 2026 and 2025.

8. TRADE AND NOTE RECEIVABLES

	As at 30 June 2026 *RMB'000* (Unaudited)	As at 31 December 2025 *RMB'000* (Audited)
Non-current assets:		
Trade receivables	**7,007**	6,867
Less: credit loss allowance	**(74)**	(74)
	6,933	6,793
Current assets:		
Trade receivables	**203,082**	151,516
Less: credit loss allowance	**(4,061)**	(3,064)
	199,021	148,452
Note receivables	**10,492**	2,697
	209,513	151,149

The credit period granted to the Group's customers is usually 30 to 90 days. As at 30 June 2026 and 31 December 2025, the aging analysis of trade receivables in current assets based on invoice date is as follows:

	As at 30 June 2026 *RMB'000* (Unaudited)	As at 31 December 2025 *RMB'000* (Audited)
0 to 90 days	**161,605**	116,796
91 to 180 days	**18,490**	12,130
181 to 365 days	**13,193**	16,978
Over 1 year	**9,794**	5,612
	203,082	151,516

Movements on the Group's credit loss allowance for trade receivables are as follows:

	For the six months ended 30 June 2026 *RMB'000* (Unaudited)	2025 *RMB'000* (Unaudited)
At beginning of the period	**3,138**	2,850
Increase in loss allowance	**997**	5,160
Written off as uncollectible	**–**	(5,285)
At end of the period	**4,135**	2,725

9. TRADE AND NOTE PAYABLES

	As at 30 June 2026	As at 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**128,577**	60,870
Note payables	**1,412**	1,412
	129,989	62,282

Trade payables were mainly denominated in RMB as at 30 June 2026 and 31 December 2025. The credit periods granted by suppliers generally range from 30 to 180 days. The aging analysis of trade and note payables, based on invoice date, is as follows:

	As at 30 June 2026	As at 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
0 to 90 days	**122,182**	61,806
91 to 180 days	**4,660**	425
Over 180 days	**3,147**	51
	129,989	62,282

Revenue

We generate revenue from the provision of (i) drug discovery solutions, and (ii) AI for Science intelligent solutions. We provide multi-disciplinary services or solutions in areas such as pharmaceuticals and materials science, as well as related products, depending on our customers' needs.

The table below sets forth a breakdown of our revenue by business line:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Drug discovery solutions	**200,109**	435,212
AI for Science intelligent solutions	**193,518**	81,864
Total	**393,627**	517,076

Our revenue decreased by 23.9% from RMB517.1 million for the six months ended 30 June 2025 to RMB393.6 million for the six months ended 30 June 2026, mainly due to the recognition of major pipeline licensing revenue in the corresponding period last year, which resulted in a higher comparison base. Excluding such impact, our revenue recorded rapid growth, representing a year-on-year increase of 73.8%.

Drug discovery solutions. Our revenue generated from our provision of drug discovery solutions decreased by 54.0% from RMB435.2 million for the six months ended 30 June 2025 to RMB200.1 million for the six months ended 30 June 2026, primarily due to the Group's recognition of an initial payment of USD51.0 million (equivalent to RMB365.1 million) from this major pipeline licensing project during the six months ended 30 June 2025, which created a high comparison base. During the six months ended 30 June 2026, this cooperation project made favorable progress, and the Group received the second payment of USD19.0 million (equivalent to RMB129.4 million) as agreed under the final agreement. The Group is actively advancing its strategic transition from services to assets. By developing its proprietary innovative drug pipeline and building a multimodal technology platform, the Group continues to accumulate high-quality assets with significant clinical value and commercialization potential, laying a solid foundation for the realization of long-term value in the future.

AI for Science intelligent solutions. Our revenue generated from our provision of AI for Science intelligent solutions increased by 136.4% from RMB81.9 million for the six months ended 30 June 2025 to RMB193.5 million for the six months ended 30 June 2026, primarily attributable to rapid expansion of new clients and high repeat purchase rates of existing clients driven by iterative technological upgrades and high-quality deliveries. Both intelligent robotic labs and intelligent services maintained a high-growth momentum.

Cost of Revenue

Our cost of revenue increased by 104.8% from RMB82.0 million for the six months ended 30 June 2025 to RMB167.8 million for the six months ended 30 June 2026, primarily attributable to the increase in fulfillment of performance obligations driven by business scale growth.

General and Administrative Expenses

Our general and administrative expenses increased by 5.9% from RMB200.3 million for the six months ended 30 June 2025 to RMB212.1 million for the six months ended 30 June 2026, primarily due to the Group's increased infrastructure investment and the increase in employee benefit expenses incurred to support business development.

Research and Development Expenses

Our R&D expenses increased by 66.0% from RMB221.5 million for the six months ended 30 June 2025 to RMB367.8 million for the six months ended 30 June 2026, primarily attributable to the Group's continued investment in autonomous laboratories and agentic system, as well as the relevant investment in the pipelines under development and multimodal technology platforms to strengthen and upgrade the Group's R&D capabilities.

Selling and Marketing Expenses

Our selling and marketing expenses increased by 18.9% from RMB40.4 million for the six months ended 30 June 2025 to RMB48.0 million for the six months ended 30 June 2026, primarily due to the increase in employee benefit expenses incurred to continuously intensify business expansion and enhance market penetration rates.

Other Income

Our other income decreased by 56.5% from RMB30.6 million for the six months ended 30 June 2025 to RMB13.3 million for the six months ended 30 June 2026, primarily due to a decrease in the government grants recognised during the Reporting Period.

Other Gains, Net

Our other gains, net increased by 259.9% from RMB37.7 million for the six months ended 30 June 2025 to RMB135.7 million for the six months ended 30 June 2026, primarily attributable to the increase in the gain on fair value of financial assets at fair value through profit or loss ("**financial assets at FVTPL**").

Operating (Loss)/profit

We recorded an operating loss of RMB254.2 million for the six months ended 30 June 2026 (2025: an operating profit of RMB32.7 million), primarily attributable to the abovementioned factors.

Finance Income, Net

Our finance income, net decreased by 35.5% from RMB48.2 million for the six months ended 30 June 2025 to RMB31.1 million for the six months ended 30 June 2026, primarily due to the incremental interest expenses arising from the liability component of newly issued convertible bonds under the effective interest rate method, partly offset by the increase in interest income on bank deposits driven by higher average deposit balances for the six months ended 30 June 2026.

(Loss)/profit for the Period

As a result of above-mentioned factors, we recorded a net loss of RMB224.9 million for the six months ended 30 June 2026 (2025: a net profit of RMB75.6 million).

Non-IFRS Measure

In evaluating our business, we consider and use adjusted net (loss)/profit, a non-IFRS financial measure, to supplement the review and assessment of our operating performance. We believe such non-IFRS measure facilitates comparisons of our operating performance from period to period by eliminating the potential impact of certain items. We believe that the measure provides useful information to investors in understanding and evaluating our consolidated results of operations in the same manner as they help our management. The use of the non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, as a substitute for analysis of, or superior to, our results of operations or financial conditions as reported under IFRS. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies, and may not be comparable to other similarly titled measures used by other companies.

We define adjusted net (loss)/profit (non-IFRS measure) as net (loss)/profit adjusted by adding back (i) share-based compensation expenses, and (ii) interest expenses on convertible bonds. Share-based compensation expenses mainly represent expenses incurred in connection with our employee stock ownership plan, reflecting equity awards granted to employees. Interest expenses on convertible bonds arise from the amortisation of separated liability component under the effective interest rate method.

The following table sets forth our adjusted net (loss)/profit (non-IFRS measure) for the periods indicated:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
(Loss)/profit for the period	**(224,944)**	75,609
Add:		
Share-based compensation expenses	**66,473**	66,019
Interest expenses on convertible bonds	**52,960**	–
Adjusted net (loss)/profit (non-IFRS measure)	**(105,511)**	141,628

Borrowings

Our borrowings increased by 764.8% from RMB345.8 million as of 31 December 2025 to RMB2,990.4 million as at 30 June 2026, reflecting the net increased balance of our convertible bonds and bank borrowings.

Our convertible bonds amounted to RMB2,460.3 million as at 30 June 2026 (31 December 2025: nil), primarily due to recognition of the separated liability component arising from the issuance of zero coupon convertible bonds on 28 January 2026. Further details are set out in the section headed "Issue of Convertible Bonds" below.

Our bank borrowings increased by 53.3% from RMB345.8 million as of 31 December 2025 to RMB530.1 million as at 30 June 2026, reflecting the net increased balance of our bank borrowings. Our bank borrowings as of 30 June 2026 were denominated in Renminbi. Some of our bank borrowings were secured by equity interests of our subsidiaries and guarantees provided by our subsidiaries. All of the bank borrowings bore fixed interest rates.

Gearing Ratio

No gearing ratio (net debt (borrowings less cash balance) divided by total equity) was presented as the Group had net cash surplus as at 30 June 2026 and 31 December 2025. At those dates, the cash balance exceeded the borrowings by RMB5,680.8 million and RMB6,722.8 million, respectively.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended 30 June 2026, we financed our capital expenditure and working capital requirements primarily through borrowings, equity fundraising and cash inflows from our business operations. We intend to continue relying on cash flows from operations and those from financing activities including net proceeds from the Global Offering, proceeds from the placing of new shares and net proceeds from the issue of Convertible Bonds. As at 30 June 2026, the sum of our cash and cash equivalents, bank deposits, current portion of financial assets at FVTPL and restricted cash was RMB8,671.2 million, as compared with RMB7,068.6 million as of 31 December 2025.

With respect to cash management, we have established treasury and investment policies, such as our treasury management policy (資金管理制度), to monitor and manage our settlement activities and financing activities (including broadening and diversification of fundraising channels and cash management tools), and to control the risks relating to bank deposits and/or the purchase of financial instruments. We place bank deposits and/or purchase financial instruments only when we have spare cash in addition to sufficient cash for our operations and in the best interest of our Company.

Issue of Convertible Bonds

On 8 January 2026, the Company announced the issue of zero coupon convertible bonds (the "**Convertible Bonds**") in an aggregate principal amount of HK$2,866,000,000. The issue of the Convertible Bonds was completed on 28 January 2026. The net proceeds from the issue of the Convertible Bonds, after deduction of fees and commissions and other estimated expenses, were approximately HK$2,839.4 million.

The Company intended to use the net proceeds from the issue of the Convertible Bonds primarily for (i) enhancing the Issuer's domestic and international research and development capabilities and one-stop-solution provision capabilities, (ii) enhancing domestic and international commercialisation capabilities and expand business development and marketing teams, (iii) expanding domestic and international delivering and research and development capabilities through site construction, and (iv) working capital and general corporate purposes.

To the extent that the net proceeds from the Convertible Bonds are not immediately used for the purposes described above, the Company may hold such unutilised proceeds in short-term deposits (and not short-term wealth management products) placed with licensed financial institutions.

CONTINGENT LIABILITIES

As of 31 December 2025 and 30 June 2026, we did not have material contingent liabilities that were expected to materially and adversely affect our financial condition or results of operations.

CAPITAL EXPENDITURES

Our capital expenditures are used to expand our operations and upgrade our facilities. For the six months ended 30 June 2025 and 2026, we incurred capital expenditures of RMB45.2 million and RMB57.2 million, respectively, primarily consisting of expenditures on property, plant and equipment and intangible assets.

FOREIGN EXCHANGE

Foreign exchange risk arises when future commercial transactions or recognised assets and liabilities are denominated in a currency that is not our entities' functional currency. We closely monitor our foreign exchange exposures and will take actions as necessary to mitigate the impact of exchange rate fluctuations.

PLEDGE OF ASSETS

As of 30 June 2026, the equity interests of one of our subsidiaries were pledged by our Group (as of 31 December 2025: one patent held by our subsidiaries and equity interests of one of our subsidiaries were pledged by our Group).

SIGNIFICANT INVESTMENTS HELD AND MATERIAL ACQUISITIONS AND DISPOSALS

As at 30 June 2026, there was no significant investment held by our Group, nor were any material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

We did not have any concrete plan for material investments or acquisition of capital assets other than those mentioned in this announcement, the prospectus of the Company dated 4 June 2024 or in our previous announcements from the listing of the Company's shares on 13 June 2024 to 30 June 2026, including the announcements on the placing of the Company's shares in 2025, and the issue of the Convertible Bonds in January 2026.

EMPLOYEES AND REMUNERATION POLICY

As of 30 June 2025 and 30 June 2026, we had a total of 1,054 and 1,623 employees, respectively. For the six months ended 30 June 2026, the total remuneration cost incurred by the Group was RMB451.8 million (six months ended 30 June 2025: RMB316.8 million).

The remuneration of our Group's employees comprises salaries, bonuses, employees' provident fund, share-based payment, and social security contributions and other welfare payments, which are determined by their responsibilities, qualifications, positions and seniority. In accordance with applicable laws and regulations, we make contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group's employees.

We provide formal and comprehensive company-level and department-level training to our new employees, followed by on-the-job training. We also provide training and development programs to our employees from time-to-time to ensure their awareness and compliance with our various policies and procedures. Some of the training is conducted jointly by departments serving different functions but working with or supporting each other in our day-to-day operations.

SUBSEQUENT EVENTS

No significant events occurred which have material impact on the performance of the Group subsequent to 30 June 2026 and up to the date of this announcement.

INTERIM DIVIDEND

The Board does not recommend the distribution of any interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company aims to achieve high standards of corporate governance, which are crucial to the Company's development and safeguard the interests of the Company's shareholders. The Company has applied the principles of good corporate governance and adopted the code provisions of the Corporate Governance Code (the "**Corporate Governance Code**") as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as its own code of corporate governance. The Company has complied with all applicable code provisions set out in Part 2 of the Corporate Governance Code during the six months ended 30 June 2026. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules (the "**Model Code**") as its own code of conduct for dealings in the securities of the Company by the Directors.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the six months ended 30 June 2026.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares). As of 30 June 2026, the Company did not hold any treasury shares.

REVIEW OF INTERIM RESULTS

The Company has established the Audit Committee with written terms of reference in compliance with the Corporate Governance Code. The Audit Committee currently consists of three independent non-executive Directors, namely, Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang. The Audit Committee is chaired by Mr. Law Cheuk Kin Stephen. The Audit Committee has reviewed the unaudited consolidated interim financial information of the Group for the Reporting Period and discussed with the management and auditors of the Company the accounting principles and practices adopted by the Group.

The interim financial information for the Reporting Period has not been audited but has been reviewed by PricewaterhouseCoopers, the auditor of the Company, in accordance with International Standard on Review Engagement 2410 "Review of interim financial information performed by the independent auditor of the entity" issued by the International Auditing and Assurance Standards Board.

PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT

This announcement is published on the respective websites of the Company (www.xtalpi.com) and the Stock Exchange (www.hkexnews.hk). The interim report for the Reporting Period will be made available on the respective websites of the Company and the Stock Exchange as and when appropriate.

By order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 19 August 2026

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.